Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Liver Transpl ; 28(8): 1321-1331, 2022 08.
Artigo em Inglês | MEDLINE | ID: mdl-35332652

RESUMO

Cardiovascular disease (CVD) significantly contributes to morbidity and mortality after liver transplantation (LT). Cirrhotic cardiomyopathy (CCM) is a risk factor for CVD after transplant. CCM criteria were originally introduced in 2005 with a revision proposed in 2020 reflecting echocardiographic technology advancements. This study assesses the two criteria sets in predicting major adverse cardiac events (MACE) after transplant. This single-center retrospective study reviewed adult LT recipients between January 1, 2009, and December 31, 2018. Patients with insufficient pre-LT echocardiographic data, prior ischemic heart disease, portopulmonary hypertension, or longitudinal care elsewhere were excluded. The primary composite outcome was MACE (arrhythmia, heart failure, cardiac arrest, and/or cardiac death) after transplant. Of 1165 patients, 210 met the eligibility criteria. CCM was present in 162 patients (77%) per the original criteria and 64 patients (30%) per the revised criteria. There were 44 MACE and 31 deaths in the study period. Of the deaths, 38.7% occurred secondary to CVD. CCM defined by the original criteria was not associated with MACE after LT (p = 0.21), but the revised definition was significantly associated with MACE (hazard ratio [HR], 1.93; 95% confidence interval, 1.05-3.56; p = 0.04) on multivariable analysis. Echocardiographic variable analysis demonstrated low septal e' as the most predictive variable for MACE after LT (HR, 3.45; p < 0.001). CCM, only when defined by the revised criteria, was associated with increased risk for MACE after LT, validating the recently revised CCM definition. Abnormal septal e', reflecting impaired relaxation, appears to be the most predictive echocardiographic criterion for MACE after LT.


Assuntos
Cardiomiopatias , Doenças Cardiovasculares , Transplante de Fígado , Adulto , Cardiomiopatias/complicações , Cardiomiopatias/etiologia , Doenças Cardiovasculares/etiologia , Humanos , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Cirrose Hepática/cirurgia , Transplante de Fígado/efeitos adversos , Estudos Retrospectivos , Fatores de Risco
2.
BMC Nephrol ; 20(1): 373, 2019 10 17.
Artigo em Inglês | MEDLINE | ID: mdl-31623566

RESUMO

BACKGROUND: Medication non-adherence is a risk factor for acute kidney transplant rejection. The association of non-adherence with short-term allograft loss in patients who develop acute rejection and are subsequently treated with maximal therapy is unknown. METHODS: We conducted a retrospective single center cohort study of adult patients who developed acute rejection from January 2003 to December 2017 and were treated with lymphocyte depletion. Clinicopathologic characteristics including adherence status were collected and descriptive statistics utilized to compare groups. The primary outcome was all-cause graft loss at 6 months after acute rejection treatment. A multivariable logistic regression quantified the association of non-adherence with the outcome. RESULTS: A total of 182 patients were included in the cohort, of whom 71 (39%) were non-adherent. Compared to adherent patients, non-adherent patients were younger (mean age 37y vs 42y), more likely to be female (51% vs 35%) and developed acute rejection later (median 2.3y vs 0.5y from transplant). There were no differences in estimated glomerular filtration rate or need for dialysis on presentation, Banff grade, or presence of antibody mediated rejection between the 2 groups. Overall, 48 (26%) patients lost their grafts at 6 months after acute rejection treatment. In adjusted analysis, non-adherence was associated with all-cause graft loss at 6 months after acute rejection treatment [OR 2.64 (95% CI 1.23-5.65, p = 0.012]. CONCLUSIONS: After adjusting for common confounders, non-adherent patients were at increased risk for short-term allograft loss after a severe acute rejection despite lymphocyte depletion. This finding may aid clinicians in risk stratifying patients for poor short-term outcomes and treatment futility.


Assuntos
Rejeição de Enxerto/tratamento farmacológico , Sobrevivência de Enxerto , Imunossupressores/uso terapêutico , Adesão à Medicação , Doença Aguda , Adulto , Fatores Etários , Alemtuzumab/uso terapêutico , Aloenxertos , Soro Antilinfocitário/uso terapêutico , Feminino , Rejeição de Enxerto/terapia , Humanos , Transplante de Rim , Depleção Linfocítica , Masculino , Pessoa de Meia-Idade , Muromonab-CD3/uso terapêutico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Fatores Sexuais , Fatores de Tempo , Adulto Jovem
3.
ACG Case Rep J ; 9(6): e00800, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-35756725

RESUMO

Sarcoidosis is a systemic disease characterized by noncaseating granulomatous inflammation. Gastrointestinal involvement in sarcoidosis is a very rare occurrence, with the colon being affected in few patients. We present a case of sarcoidosis presenting as multiple colonic polyps found on routine colorectal cancer screening colonoscopy. Histopathology of the polyps showed noncaseating granulomas.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA